Materialise NV: Third Quarter 2025 Financial Summary
Business Context and Reporting Period
This Form 6-K reports the unaudited financial results for Materialise NV for the third quarter ended September 30, 2025. Materialise is a global provider of 3D printing software and services, operating through three primary segments: Materialise Medical, Materialise Software, and Materialise Manufacturing.
Key Financial Metrics
| Metric | Q3 2025 (kEUR) | Q3 2024 (kEUR) | Change |
|---|---|---|---|
| Total Revenue | 66,259 | 68,652 | -3.5% |
| Gross Profit | 37,651 | 39,297 | -4.2% |
| Gross Margin | 56.8% | 57.2% | -0.4 pp |
| Operating Profit | 2,522 | 4,313 | -41.5% |
| Net Profit | 1,848 | 3,038 | -39.2% |
| Adjusted EBITDA | 8,428 | 9,895 | -14.8% |
| Cash & Equivalents | 132,022 | 102,304 (Dec 2024) | +29.0% |
| Gross Debt | 64,278 | 41,284 (Dec 2024) | +55.7% |
| Net Cash Position | 67,744 | 61,020 (Dec 2024) | +11.0% |
Material Changes vs. Prior Period
- Revenue Mix Shift: Total revenue declined 3.5% year-over-year. This was driven by a 17.1% drop in the Manufacturing segment (22,677 kEUR) and a 7.4% decline in the Software segment (10,286 kEUR). Conversely, the Medical segment grew 10.3% to 33,296 kEUR.
- Profitability Compression: Operating profit fell significantly to 2,522 kEUR from 4,313 kEUR. While operational expenses increased only slightly (0.5%), the revenue decline and lower gross margin (56.8% vs 57.2%) pressured results.
- Segment Performance: The Manufacturing segment turned negative on an Adjusted EBITDA basis, reporting (845) kEUR compared to 701 kEUR in Q3 2024. The Medical segment remained the primary profit driver with 10,199 kEUR in Adjusted EBITDA.
- Balance Sheet: Gross debt increased substantially to 64,278 kEUR from 41,284 kEUR at year-end 2024, primarily due to new loan proceeds of 35,000 kEUR in the first nine months of 2025. Despite higher debt, the net cash position improved due to strong cash reserves.
Outlook, Commentary, and Risks
- Management Commentary: The company highlighted increased R&D investments (up 4.2%) focused on the Medical segment. Operational expenses were tightly controlled, rising only 0.5% in aggregate.
- Non-IFRS Measures: Adjusted EBIT margin decreased to 4.4% from 6.4% in the prior year. Adjusted EBITDA margin was 12.7% compared to 14.4% in Q3 2024.
- Unusual Items: The reconciliation of net profit to Adjusted EBITDA includes 322 kEUR in restructuring and corporate initiative costs for Q3 2025, compared to zero in Q3 2024.
- Risks: The filing notes that non-IFRS measures do not reflect cash requirements for debt service or periodic costs of capitalized assets. The significant decline in the Manufacturing segment's profitability represents a key operational risk.
Investor Verification Checklist
- Verify the sustainability of the 17.1% revenue decline in the Manufacturing segment and the cause of its negative Adjusted EBITDA.
- Assess the impact of the 55.7% increase in gross debt on future interest expenses and liquidity.
- Confirm the trajectory of the Medical segment's growth, which offset declines in other areas.
- Review the specific nature of the 322 kEUR in restructuring costs included in Adjusted EBITDA.
- Monitor the trend in gross margins, which have compressed slightly to 56.8%.